Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation

Namita Singh, MD,1 Ana P. Rossi, MD,1 Marizela Savic, PharmD,2 Ronald J. Rubocki, PhD,3 Mark G. Parker, MD,1 and John P. Vella, MD1

Background. Rabbit antithymocyte globulin (rATG) is the most widely used kidney transplant induction immunotherapy in the United States. It was recently Food and Drug Administration approved for this indication with typical dose recommendations of 1.5 mg/kg for up to 7 days given via a central line. Methods. We theorized that reduced rATG dosing when compared with conventional dosing (6-10.5 mg/kg) is safe and effective, leading to development of a risk-stratified treatment protocol. Five-year data from a retrospective cohort of 224 adult kidney transplants (2008-2013) with follow-up through 2015 is presented. Cumulative rATG doses of 3 mg/kg were administered peripherally to nonsensitized living donor recipients, 4.5 mg/kg to nonsensitized deceased donor recipients. A subset of higher immunologic risk recipients (defined as history of prior transplant, panel reactive antibody greater than 20%, or flow cytometry crossmatch positivity) received 6 mg/kg. Results. There were no differences in patient or graft survival between the 3 groups. One-year rejection rates in the first 2 groups were 8.3% and 8.8%, respectively, comparable to contemporaneous rates reported to the Scientific Registry of Transplant Recipients. Dose tailoring permitted substantial cost savings estimated at US $1,091,502. Mean length of stay fell by almost 3 days as the protocol was refined. There were no episodes of phlebitis. Infection rates were comparable with those reported to the Scientific Registry of Transplant Recipients. Conclusions. The novel findings of the current study include peripheral administration, reduced dosing, favorable safety, excellent allograft outcomes, and clear associative data regarding reduced costs and length of stay.

Received 28 June 2017. Revision requested 19 November 2017. Accepted 22 November 2017.

1 Division of Nephrology and Transplantation, Maine Medical Center, Portland, ME.
2 Department of Pharmacy, Maine Medical Center, Portland, ME.
3 NorDx HLA Laboratory, Portland, ME.

This work was presented orally at the American Transplant Congress, 6/14/16 by N Singh on behalf of the authors.
The present study did not receive funding from any external sources.

J.P.V. discloses research contracts with Astellas and Bristol Myers Squibb.

N.S. participated in research design, data collection and analysis, and writing of the article. A.P.R. and J.P.V. participated in research design, statistical analysis and writing of the article. M.S. and R.J.R. participated in research design, data collection and writing of the article. M.G.P. participated in research design and writing of the article.

Correspondence: Namita Singh, MD, Maine General Medical Center, 35 Medical Center Parkway, Augusta, ME 04330. (dnamitaasingh@gmail.com).

Copyright © 2018 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000765

(Transplantation Direct 2018;4: e343; doi: 10.1097/TXD.0000000000000765. Published online 23 January, 2018.)
Sixteen years of internal quality data analyses permitted development of the risk-stratified dosing strategy that is presented herein.

**MATERIALS AND METHODS**

**Study Design and Patient Population**

A single-center retrospective cohort study encompassing adult kidney transplants performed at Maine Medical Center between July 1, 2008, and December 31, 2013, is presented. All patients included in the study were followed through January 1, 2015. Recipients were divided in three groups according to the administered rATG dose. Cumulative rATG doses of 3 mg/kg were administered to nonsensitized living donor recipients and 4.5 mg/kg to nonsensitized deceased donor recipients. An increased immunologic risk subgroup (defined as history of prior transplant, panel reactive antibody greater than 20%, or flow cytometry crossmatch positivity defined as a 40 and 100 channel shift for T and B lymphocytes respectively using a 1024 channel Beckman-Coulter FC-500 Cytometer) received 6 mg/kg (Table 1A). The rATG dose was calculated using the actual weight of the patients. Minor protocol deviations occurred in less than 7% of cases. The first dose of rATG given intraoperatively via a peripheral intravenous access was 1.5 mg/kg until November 2010, after which the dose was increased to 3 mg/kg to facilitate earlier discharge and to reduce length of stay (LOS). The time frame for subsequent doses of 1.5 mg/kg was dictated by clinical progress and physician discretion.

**Maintenance Immunosuppression Therapy**

All patients received a cumulative loading dose of methylprednisolone 1 gram perioperatively after which prednisone was started at 30 mg daily tapering to 5 mg daily by week 10. Mycophenolate mofetil was started at 1000 mg twice daily immediately posttransplantation, with dose adjustments for adverse effects as necessary. Tacrolimus 0.05 mg/kg was administered twice daily aiming for trough levels of 10 to 12 ng/mL for the first 3 months, and was lowered to 7 to 10 ng/mL until the end of the first year. The goal was to maintain triple immunotherapy unless adverse effects dictated otherwise.

**Antimicrobial Prophylaxis**

Bacterial and *Pneumocystis jirovicii* pneumonia prophylaxis was achieved with trimethoprim-sulfamethoxazole single-strength daily for 1 year. For patients allergic to sulfa products, inhaled pentamidine or oral atovaquone were administered. Oral candida prophylaxis included clotrimazole or oral nystatin for the first month posttransplantation. For cytomegalovirus (CMV) prophylaxis, choice and duration of antiviral depended on the donor and recipient risk profile. CMV negative patients receiving a CMV positive donor kidney received 24 weeks of valganciclovir. CMV positive

### TABLE 1A.

| Baseline recipient characteristics | All recipients (n = 224)* | rATG, 3 mg/kg (n = 96) | rATG, 4.5 mg/kg (n = 102) | rATG, 6 mg/kg (n = 26) |
|-----------------------------------|--------------------------|-----------------------|--------------------------|-----------------------|
| Mean age (± SD), y                | 49.6 ± 12.7              | 49 ± 13.5             | 52 ± 11.2                | 45 ± 14               |
| Male sex, n (%)                   | 151 (67.4)               | 63 (65.6)             | 74 (72.5)                | 14 (53.8)             |
| White, n (%)                      | 215 (96)                 | 92 (95.8)             | 98 (96.1)                | 25 (96.2)             |
| ESRD etiology                     |                          |                       |                         |                       |
| Chronic GN                       | 79 (35.3)                | 38 (39.6)             | 33 (32.4)                | 8 (30.8) |
| Diabetes mellitus                 | 50 (22.3)                | 23 (24.0)             | 27 (26.5)                | 0                     |
| Hypertension                      | 25 (11.2)                | 8 (8.3)               | 16 (15.7)                | 1 (3.8)               |
| Obstructive uropathy              | 24 (10.7)                | 9 (9.4)               | 3 (2.9)                  | 12 (46.2)             |
| Polycystic kidney disease         | 26 (11.6)                | 8 (8.3)               | 16 (15.7)                | 2 (7.7)               |
| Other                             | 20 (8.9)                 | 10 (10.4)             | 7 (6.9)                  | 3 (11.4)              |
| Preemptive, n (%)                 | 27 (12.1)                | 25 (26.9)             | 1 (1)                    | 1 (3.8)               |
| Deceased donor, n (%)             | 118 (52.7)               | 4 (4.2)               | 93 (91.2)                | 21 (80.8)             |
| History previous transplant, n (%)| 37 (16.9)                | 1 (0.1)               | 13 (12.7)                | 23 (88.9)             |
| Mean HLA mismatch ± SD           | 3.9 ± 1.6                | 3.4 ± 1.7             | 4.5 ± 1.1                | 3.2 ± 2.1             |
| Mean Cumulative rATG dosage delivered (±SD), mg/kg | 4.0 ± 1.0 | 3.0 ± 0.0 | 4.5 ± 0.0 | 6.1 ± 0.3 |
| Maintenance immunosuppression, n (%) |                       |                       |                         |                       |
| Calcineurin inhibitor             | 224 (100)                | 96 (100)              | 102 (100)                | 26 (100)              |
| Antimetabolite                    | 211 (94.2)               | 88 (91.7)             | 97 (95.1)                | 26 (100)              |
| Steroid                           | 224 (100)                | 96 (100)              | 102 (100)                | 26 (100)              |
| Mean follow-up (±SD), mo          | 42.3 ± 20.0              | 43 ± 18.8             | 42 ± 20.7                | 39 ± 22.2             |

rATG, rabbit antithymocyte globulin; ESRD, end-stage renal disease; DDRT, deceased donor renal transplant; PRA, panel reactive antibody.

---

**TABLE 1B.**

| Exclusion criteria                 | n  |
|------------------------------------|----|
| No immunosuppression               | 2  |
| 1 Identical Twin Transplant        |    |
| 1 Kidney transplant from prior bone marrow donor |    |
| IL-2R induction therapy           | 5  |
| rATG therapy interrupted          | 3  |
| Graft thrombosis                   | 4  |
| Death within 1 month of transplant | 3  |
| Total                              | 17 |

*Two hundred twenty-four of the initial 241 adult patients transplanted in the study period (93%) were included in the analysis. Six pediatric transplant recipients were also excluded.*
recipients received 12 weeks of valganciclovir. Seronegative recipients of seronegative allografts received 12 weeks of acyclovir to prevent non-CMV herpes infection. Antiviral agents were dosed according to the estimated glomerular filtration rate.

**Statistical Analysis**

The primary outcome of the study was biopsy-proven acute rejection (BPAR) within the first year posttransplant. The secondary outcomes included patient survival, graft survival, costs and LOS. Patient demographics, baseline characteristics and primary outcome were summarized using descriptive statistics. Kaplan-Meier analysis was used to estimate rejection-free survival as well as graft and patient survival. Log-rank test was used to compare survival distributions.

The study was deemed exempt from the Institutional Review Board as it involved collection and analysis of existing data in such a manner that subjects could not be identified.

**RESULTS**

The patient demographics are described in Table 1A. Importantly, 224 of the initial 241 patients transplanted in the study period (93%) were included in the analysis. Seventeen patients were excluded for various reasons described in Table 1B. The median follow-up was 42 months. Consistent with the demographics of northern New England, 96% of patients were Caucasian. All patients had negative crossmatches, both by CDC and flow cytometry.

The outcomes of the groups based on the cumulative rATG dosing are described in Table 2 and Figures 1 to 3. There were no significant differences in rejection, graft or patient survival between the 3 groups. The mean serum creatinine at 1 year was 1.5 mg/dL for all patients. However, the increased immunologic risk group who received higher dose rATG (6 mg/kg) was smaller, underwent numerically (if not significantly) more allograft biopsies, had earlier time to biopsy, more donor-specific antibodies (DSA), more rejection, and had higher serum creatinine levels at 1 year as expected.

**TABLE 2.** Outcomes based on the cumulative rATG dosages

|                        | All recipients (n = 224) | rATG, 3 mg/kg (n = 96) | rATG, 4.5 mg/kg (n = 102) | rATG, 6 mg/kg (n = 26) |
|------------------------|-------------------------|-----------------------|--------------------------|-----------------------|
| Mean serum creatinine at 1 y (±SD), mg/dL | 1.5 ± 0.6               | 1.5 ± 0.5             | 1.5 ± 0.5                | 1.8 ± 0.9             |
| No. biopsies           | 87 (39%)                | 33 (34%)              | 34 (33%)                 | 20 (76%)              |
| No. patients with one or more biopsies, n (%) | 71 (31.7)               | 29 (30.2)             | 27 (26.5)                | 15 (57.7)             |
| Mean time to first biopsy (± SD), d          | 118 ± 102               | 144 ± 110             | 116 ± 100                | 71 ± 69               |
| DSA screen, n (%)      | 97 (43.3)               | 46 (47.9)             | 34 (33.3)                | 17 (65.4)             |
| DSA positivity, n (%)  | 16 (7.1)                | 7 (7.3)               | 6 (5.9)                  | 3 (11.4)              |
| Class I                | 18 (8.0)                | 10 (10.4)             | 4 (3.9)                  | 4 (15.4)              |
| Class II               |                         |                       |                          |                       |
| No. patients with BPAR, n (%)      | 21 (9.4)                | 8 (8.3)               | 9 (8.8)                  | 4 (15.4)              |
| No. BPAR episodes       | 29 (12.9%)              | 9 (9.3%)              | 13 (12.7%)               | 7 (26.9%)             |
| Death-censored graft survival  |                        |                       |                          |                       |
| 1-year, n (%)           | 224 (100)               | 96 (100)              | 102 (100)                | 26 (100)              |
| End-of-study, * n (%)   | 212 (94.6)              | 90 (93.8)             | 99 (97.1)                | 23 (88.5)             |
| Deaths at 1 y, n (%)    | 8 (3.6)                 | 2 (2.1)               | 4 (3.9)                  | 2 (7.7)               |
| Deaths at the end of study, n (%) | 15 (6.7)                | 4 (4.2)               | 9 (8.8)                  | 2 (7.7)               |

* End-of-study, January 1, 2015.

*At risk* patients (retransplant, prior acute rejection, increased PRA) were screened for DSA. DSA also tested for cause (AKI, proteinuria). DSA defined as > 1000 MFI for detection of HLA Ab. BPAR, biopsy proven acute rejection.

**FIGURE 1.** Kaplan-Meier curves for rejection-free survival for the 3 rATG groups indicate that there was no difference between the groups.

**FIGURE 2.** Kaplan-Meier curves for graft survival for the 3 rATG groups indicate no difference between the 3 groups.
Detailed analysis of allograft rejection is described in Tables 3A and 3B. There were 29 BPAR episodes (12.9%) in 21 patients (9.4%). Thirty-eight percent of the rejections were antibody mediated, most of which were treated with plasmapheresis and IVIg. Sixty-two percent were T-cell mediated, most of which were treated with lympholytic doses of methylprednisolone and augmented maintenance immunotherapy. These rejection rate was lower than that seen in historic controls (approximately 20%, data not shown) who had not received rATG induction therapy.

Analysis of rATG cost is described in Figure 4 and Table 4. Cost expenditure was derived based on a purchasing price of US $697 per 25 mg vial of rATG. A total of US $2,272,220 was spent on rATG for these 224 patients averaging US $10,143 per patient. The mean cost per patient was US $7,667 in the 3-mg/kg rATG group, US $11,152 in the 4.5-mg/kg group, and US $15,334 in the 6-mg/kg rATG group. Dose tailoring permitted substantial cost savings on rATG alone estimated at US $1,091,502 over the study period compared with routine rATG dosing of 6 mg/kg.

To streamline care, minimize duration of cytokine release symptoms and thus promote patient education and early discharge, the intraoperative rATG dose was increased from 1.5 to 3 mg/kg starting November 2010. Since making the change, the average length of hospital stay has declined from 6.8 to 4.0 days (Figure 5).

Infection rates within the first year posttransplantation were surveyed periodically during this period. Overall infection rates did not change during the study and were similar.

### TABLE 3A

Pathology according to the Banff 1997 classification with 2005 update

| Rejection type | Criteria | All episodes (n = 29) | rATG, 3 mg/kg | rATG, 4.5 mg/kg | rATG, 6 mg/kg |
|---------------|----------|----------------------|---------------|-----------------|---------------|
| AMR           |          | 11 (37.9%)           | 2 (6.9%)      | 4 (13.8%)       | 5 (17.2%)     |
| Borderline    | C4d- , changes suspicious for changes | 1 | 0 | 1 | 0 |
| Grade I       | C4d+ , acute-tubular necrosis-like | 8 | 2 | 3 | 3 |
| Grade II      | C4d+ , capillary polymorphonuclear leukocytes, and/or thrombosis | 2 | 0 | 0 | 2 |
| Grade III     | C4d+ , transmural arteritis, fibrinoid necrosis | 0 | 0 | 0 | 0 |
| Chronic       | C4d+ , capillary double contours, peritubular capillary multilayers | 0 | 0 | 0 | 0 |
| TCMR          |          | 18 (62.1%)           | 7 (24.1%)     | 9 (31.0%)       | 2 (6.9%)      |
| Borderline    | Suspicious for rejection | 4 | 1 | 3 | 0 |
| Grade I       | Intimal arteritis (>25% of parenchyma) | 13 | 5 | 6 | 2 |
| Moderate or severe tubulitis (>4 lymphocytes per tubular cross section) | | | |
| Grade II      | Transmural arteritis and/or fibrinoid necrosis with lymphocytes | 0 | 0 | 0 | 0 |
| Chronic       | Features of chronic and acute rejection | 0 | 0 | 0 | 0 |

AMR, antibody-mediated (humoral) rejection; TCMR, T cell-mediated rejection.

### TABLE 3B

Allograft rejection management

| All rejection episodes | rATG, 3 mg/kg | rATG, 4.5 mg/kg | rATG, 6 mg/kg |
|------------------------|---------------|-----------------|---------------|
| AMR                    |               |                 |               |
| Plasmapheresis         | 11            | 2               | 4             | 5             |
| Pulse dose steroids    | 11            | 2               | 4             | 5             |
| Eculizumab             | 1             | 0               | 0             | 1             |
| TCMR                   |               |                 |               |
| Thymoglobulin          | 4             | 1               | 3             | 0             |
| Pulse dose steroids    | 13            | 5               | 6             | 2             |
| Augmentation of maintenance immunosuppression | 16 | 7 | 7 | 2 |
DISCUSSION

This cohort study demonstrates that in standard immunologic-risk living and deceased donor recipients, cumulative rATG doses of 3 and 4.5 mg/kg, respectively, associates with excellent patient survival, graft survival, and low 1-year allograft rejection rates. Furthermore, allograft function, allograft survival, and patient survival at 1 year were comparable between the various rATG dosing groups. Dose tailoring permitted substantial cost savings compared with routine rATG dosing of 6 to 10.5 mg/kg as recommended in the Thymoglobulin package insert.

The overall rejection rate in the entire cohort was 9%, with living donor recipient rejection rate of 7.5% and deceased donor recipient rejection rate of 11%, comparable with that reported by the United States Renal Data System contemporaneously. The present rejection rates are far lower than institutional historic controls who had not received rATG induction therapy. The administration of rATG 3 mg/kg intraoperatively was associated with a substantive reduction in LOS. We believe this is due to a combination of less frequent dosing and also minimization of adverse events related to cytokine release, thus promoting patient education which in turn facilitates discharge planning.

Several studies have directly compared cumulative rATG dosing with outcomes, all of which used higher doses than we are describing. The initial landmark study by Brennan et al in 1996 was conducted using doses starting at 10.5 mg/kg wherein recipients received 1.5 mg/kg per day for seven consecutive days. Subsequent reports have yielded rejection rates of 10% or less albeit with higher rATG dosing than we have used. For example, Agha et al compared their historical 7-day regime in 48 patients with a modified 3-day regime in 40 patients resulting in cumulative dosing of 6 mg/kg. Similarly, Gurk-Turner et al performed a retrospective cohort study of 96 adult subjects who received between 5.7 and 10 mg/kg rATG. Klem at al reported a study in which cumulative rATG doses of 4.5 and 6 mg/kg were administered. Rogers et al reported their experience with two different rATG induction dosing and early steroid withdrawal with dosing ranges of 4.1 to 5.1 mg/kg. Single-dose administration of rATG 6 mg/kg has also been evaluated. For example, Stevens et al reported results of their experience of rATG 6 mg/kg single dose versus same total dose divided in 4 days. Again, low rejection rates with favorable safety parameters were obtained using higher doses than we report.

The advantages of this study compared with the published literature include large population size, robust follow-up over a long period and tight adherence to the treatment regimen. We identified a lower risk group that may benefit from reduced rATG dosing. The chief drawbacks include the retrospective nature of the study and the predominantly Caucasian study population. The data on the small, higher immunologic risk group are included for the sake of completeness. The numerically, if not statistically, higher incidences of DSA, biopsies, and rejection in this increased risk group are acknowledged.

In conclusion, the novel findings of the current study of reduced rATG induction therapy include peripheral administration, much reduced dosing compared with other reports, favorable safety, excellent allograft outcomes, and clear associative data regarding reduced costs and LOS.

### TABLE 4.

| Total and mean cost of rATG per cumulative dose received | All patients (n = 224) | rATG, 3 mg/kg (n = 96) | rATG, 4.5 mg/kg (n = 102) | rATG, 6 mg/kg (n = 26) |
|----------------------------------------------------------|------------------------|------------------------|------------------------|------------------------|
| Total cost of rATG, US $                                 | 2 272 220              | 736 032                | 1 137 504              | 398 684                |
| Mean cost of rATG per patient, US $                      | 10 143                 | 7667                   | 11 152                 | 15 334                 |
ACKNOWLEDGMENTS
The authors thank John Currie for assistance with data collection.

REFERENCES
1. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66(1 Suppl 1): S1–S21. S305.
2. Mannick JA, Davis RC, Cooperband SR, et al. Clinical use of rabbit antihuman lymphocyte globulin in cadaver-kidney transplantation. N Engl J Med. 1971;284:1109–1115.
3. Cardella CJ, Catrall D, Fenton SA, et al. Induction therapy with rabbit antithymocyte sera reduces rejection episodes in immunologically low-risk living donor renal transplant recipients. Transplant Proc. 1997;29: 295–315.
4. Szczesn LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol. 1997;8:1771–1777.
5. Brennan DC, Schnitzler MA, Baty JD, et al. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients. Pharmacoeconomics. 1997;11:237–245.
6. Guttmann RD, Remming C. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. Clin Transplant. 1997; 11:185–192.
7. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1995;67:1011–1016.
8. Hardinger KL, Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy. 2006;26:1771–1783.
9. Thiyagarajan UM, Ponnuswamy A, Bagul A. Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol. 2013;37:596–601.
10. Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transpl Int. 2013;26:662–672.
11. Stevens RB, Foster KW, Miles CD, et al. A Randomized 2x2 factorial clinical trial of renal transplantation: steroid-free maintenance immunosuppression with calcineurin inhibitor withdrawal after six months associates with improved renal function and reduced chronic histopathology. PLoS One. 2015;10:e0139247.
12. Stevens RB, Wrenshall LE, Miles CD, et al. A double-blind, double-dummy, flexible-design randomized multicenter trial: early safety of single-versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation. Am J Transplant. 2016;16:1858–1867.
13. Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002;73:473–475.
14. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation. 2004;78:136–141.
15. Brennan DC, Daller JA, Lake KD, et al. Thymoglobulin induction study G. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355:1967–1977.
16. Hardinger KL, Rhee S, Buchanan P, et al. A prospective, randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy: 10-year results. Transplantation. 2008;86: 947–952.
17. Hardinger KL, Rasu RS, Skelton R, et al. Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant. 2010;2010:957549.
18. Gaber AO, Matas AJ, Henry ML, et al. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation. 2012;94:331–337.
19. Wagner SJ, Brennan DC. Induction therapy in renal transplant recipients: how convincing is the current evidence? Drugs. 2012;72:671–685.
20. Lentine KL, Schnitzler MA, Xiao H, et al. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants. Trials. 2015; 16:365.
21. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72:1050–1055.
22. Tanriver B, Chiang P, Fishbach B, et al. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80:279–281.
23. Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73:1514–1519.
24. Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high-risk kidney transplant recipients. Transplantation. 2008;85:1425–1430.
25. Klem P, Cooper JE, Weiss AS, et al. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation. 2009;88:691–696.
26. Rogers CG, Asperenio N, Honvedet T, et al. Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras. Am J Nephrol. 2013;38:397–404.